US 12,168,040 B2
Sequence specific antimicrobials
David Bikard, Paris (FR); and Luciano Marraffini, Brooklyn, NY (US)
Assigned to The Rockefeller University, New York, NY (US)
Filed by The Rockefeller University, New York, NY (US)
Filed on Feb. 5, 2021, as Appl. No. 17/168,971.
Application 17/168,971 is a division of application No. 16/877,010, filed on May 18, 2020.
Application 17/168,971 is a division of application No. 16/877,030, filed on May 18, 2020, granted, now 11,135,273.
Application 17/168,971 is a division of application No. 15/159,929, filed on May 20, 2016, granted, now 11,918,631.
Application 16/877,030 is a division of application No. 15/159,929, filed on May 20, 2016, granted, now 11,918,631.
Application 15/159,929 is a division of application No. 14/766,675, granted, now 10,660,943, issued on May 26, 2020, previously published as PCT/US2014/015252, filed on Feb. 7, 2014.
Application 16/877,010 is a continuation of application No. 14/766,675, granted, now 10,660,943, issued on May 26, 2020, previously published as PCT/US2014/015252, filed on Feb. 7, 2014.
Claims priority of provisional application 61/761,971, filed on Feb. 7, 2013.
Prior Publication US 2021/0162022 A1, Jun. 3, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/46 (2006.01); A01N 63/00 (2020.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); C12N 9/16 (2006.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01); C12N 15/74 (2006.01)
CPC A61K 38/465 (2013.01) [A01N 63/00 (2013.01); A61K 31/7105 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); C12N 9/16 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 15/74 (2013.01); C12Y 301/00 (2013.01); C12N 2310/10 (2013.01); C12N 2310/20 (2017.05); C12N 2795/10331 (2013.01); C12N 2795/10332 (2013.01); C12N 2795/10343 (2013.01); C12N 2795/10371 (2013.01)] 12 Claims
 
1. A method comprising:
exposing a microbiota in a human patient to an antimicrobial agent to selectively kill cells of a first bacterial species in the microbiota,
wherein selectively killing the cells of the first bacterial species is carried out by cutting a target site comprised by the genomes of the first bacterial species,
wherein the cutting is carried out using a Cas nuclease of a Type I, Type II, or Type III CRISPR system that cleaves the target site; and
wherein the selective killing is carried out by avoiding killing second cells comprised by the microbiota, wherein the second cells are of a different strain or a different species from the cells of the first bacterial species.